Loading...
•
Mar 31
Fate Therapeutics Q1 2025 Earnings Report
Fate Therapeutics reported first quarter 2025 financial results and business updates.
Key Takeaways
Fate Therapeutics reported total revenue of $1.6 million and a net loss of $41.3 million for the first quarter of 2025. The company ended the quarter with $272.7 million in cash, cash equivalents, and investments, providing a projected operating runway through the first half of 2027. Key business updates included positive developments for their FT819 program, including RMAT designation from the FDA and expansion of the Phase 1 study.
Total revenue for Q1 2025 was $1.6 million, derived from preclinical development activities for a collaboration candidate with Ono Pharmaceutical.
Net loss for Q1 2025 was $41.3 million.
Cash, cash equivalents, and investments totaled $272.7 million as of March 31, 2025, providing a projected operating runway through the first half of 2027.
FT819 received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for moderate-to-severe Systemic Lupus Erythematosus (SLE).
Fate Therapeutics
Fate Therapeutics
Forward Guidance
Fate Therapeutics projects its cash runway to extend through the first half of 2027 based on its current cash, cash equivalents, and investments.
Positive Outlook
- Projected operating runway through 1H27 based on current cash position.
- Expansion of FT819 Phase 1 study to include additional B cell-mediated autoimmune diseases.
- Initiation of regulatory submissions in Europe for the FT819 program.
- Presentation of new clinical data for FT819 at the EULAR 2025 Congress.
- Ongoing dose escalation in the Phase 1 study for FT825 / ONO-8250 in advanced solid tumors.
Challenges Ahead
- No specific negative forward guidance points were mentioned in the report.